Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Cases. Apr 16, 2026; 14(11): 119699
Published online Apr 16, 2026. doi: 10.12998/wjcc.v14.i11.119699
Published online Apr 16, 2026. doi: 10.12998/wjcc.v14.i11.119699
Hypertrophic cardiomyopathy in the context of primary hyperaldosteronism, Sjögren’s syndrome, and obstructive uropathy: A case report
Esranur Aydoğan, Sinem Ülke, Pelin Yumuşak, Sevil Uygun İlikhan, Selma Karaahmetoğlu, Department of Internal Medicine, Ankara Bilkent City Hospital, Ankara 06690, Türkiye
Author contributions: Uygun İlikhan S and Ülke S contributed to patient evaluation and data collection; Karaahmetoğlu S and Yumuşak P contributed to diagnostic interpretation and clinical assessment; Aydoğan EN contributed to the literature review; Ülke S drafted the manuscript; and all authors critically revised the manuscript and approved the final version.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and the accompanying images.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Sinem Ülke, MD, Consultant, FRCPA, FRCPC, Department of Internal Medicine, Ankara Bilkent City Hospital, University District, Bilkent Boulevard No. 1 Çankaya, Ankara 06800, Türkiye. sinem.karaoglu384@gmail.com
Received: February 3, 2026
Revised: February 20, 2026
Accepted: March 12, 2026
Published online: April 16, 2026
Processing time: 65 Days and 7.9 Hours
Revised: February 20, 2026
Accepted: March 12, 2026
Published online: April 16, 2026
Processing time: 65 Days and 7.9 Hours
Core Tip
Core Tip: Hypertrophic cardiomyopathy-like phenotypes without identifiable genetic mutations may arise from secondary systemic conditions rather than primary sarcomeric disease alone. This case highlights the rare coexistence of primary hyperaldosteronism, Sjögren’s syndrome, and obstructive uropathy contributing synergistically to myocardial hypertrophy and fibrosis. Recognition of endocrine and autoimmune contributors is essential, as targeted treatment may help limit disease progression and improve outcomes.